XJPX
3079
Market cap67mUSD
Apr 10, Last price
1,030.00JPY
1D
-0.96%
1Q
-14.66%
Jan 2017
-24.87%
IPO
399.39%
Name
DVx Inc
Chart & Performance
P/E
26.37
P/S
0.21
EPS
39.06
Div Yield, %
4.85%
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
2.42%
Revenues
50.32b
+9.75%
Net income
410m
+137.18%
CFO
726m
P
Dividend
Mar 30, 202650 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
DVx Inc. engages in the import/export of medical devices and related peripheral devices in Japan. The company sells arrhythmia-related products, such as cardiac pacemakers, implantable cardioverter defibrillators, electrode catheters, and ablation catheters. It also offers ischemia-related products, including excimer laser systems; RADPAD, which reduces scatter radiation exposure to medical personnel during fluoroscopy procedures; RADNEK that reduces scatter radiation exposure to the thyroid in medical personnel during fluoroscopy procedures; RADCAP, which reduces scatter radiation exposure to the head of medical personnel during fluoroscopy procedures; and resolution/resolution SD and wonder belt products. In addition, the company engages in the research, development, manufacture, sale, repair, and leasing of medical devices and related peripheral devices; provision of internal and external medical and medical device-related general consulting and services; and medical publishing and market research activities. DVx Inc. was founded in 1986 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||